COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients.
Adult
Antiretroviral Therapy, Highly Active
Betacoronavirus
/ drug effects
COVID-19
Coinfection
Coronavirus Infections
/ drug therapy
Darunavir
/ therapeutic use
Female
HIV
/ drug effects
HIV Infections
/ drug therapy
Humans
Male
Middle Aged
Pandemics
Pneumonia, Viral
/ drug therapy
Retrospective Studies
SARS-CoV-2
Severity of Illness Index
Survival Analysis
Tenofovir
/ therapeutic use
Viral Load
/ drug effects
AIDS
Antiretroviral therapy
COVID-19
HIV infection
SARS-CoV-2
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
21
04
2020
accepted:
01
05
2020
pubmed:
13
5
2020
medline:
8
10
2020
entrez:
13
5
2020
Statut:
ppublish
Résumé
Data on people living with human immunodeficiency virus (PLWH) in the current SARS-CoV-2 pandemic are still scarce. This case series of 33 PLWH patients with COVID-19 reveals symptoms and outcome in this special population. Retrospective analysis of anonymized data including age, gender, HIV-associated parameters, symptoms, and outcome. Three out of 32 patients with documented outcomes died (9%). 91% of the patients recovered and 76% have been classified as mild cases. All patients were on antiretroviral treatment, of them 22 on tenofovir-containing regimen and 4 on the protease inhibitor darunavir. This preliminary case series does not support excess morbidity and mortality among symptomatic COVID-19 PLWH and with viral suppression on ART. SARS-CoV-2 infections may occur during boosted darunavir-based and/or on tenofovir-containing ART.
Identifiants
pubmed: 32394344
doi: 10.1007/s15010-020-01438-z
pii: 10.1007/s15010-020-01438-z
pmc: PMC7211976
doi:
Substances chimiques
Tenofovir
99YXE507IL
Darunavir
YO603Y8113
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
681-686Références
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
J Hosp Infect. 2019 Jan;101(1):42-46
pubmed: 30240813
Biosci Trends. 2020 Mar 16;14(1):64-68
pubmed: 32037389
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
J Korean Med Sci. 2020 Feb 17;35(6):e79
pubmed: 32056407
Lancet HIV. 2020 May;7(5):e314-e316
pubmed: 32304642
Int J Infect Dis. 2005 Nov;9(6):323-30
pubmed: 16095942
Infection. 2019 Apr;47(2):247-255
pubmed: 30414065
AIDS. 2004 Mar 26;18(5):829-30
pubmed: 15075525
PLoS One. 2014 Jul 08;9(7):e101785
pubmed: 25004134
JAMA. 2020 May 12;323(18):1824-1836
pubmed: 32282022
Clin Infect Dis. 2011 Jan 1;52 Suppl 1:S183-8
pubmed: 21342893
Euro Surveill. 2020 Mar;25(10):
pubmed: 32183930
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Crit Care. 2020 Mar 18;24(1):108
pubmed: 32188484
N Engl J Med. 2020 Jun 11;382(24):2302-2315
pubmed: 32289214
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Intern Med. 2020 Jul;288(1):128-138
pubmed: 32220033
PLoS One. 2019 Jan 16;14(1):e0209605
pubmed: 30650082
Life Sci. 2020 Jul 15;253:117592
pubmed: 32222463
J Med Virol. 2020 Jun;92(6):529-530
pubmed: 32160316
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541